HRP20210528T1 - Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma - Google Patents

Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma Download PDF

Info

Publication number
HRP20210528T1
HRP20210528T1 HRP20210528TT HRP20210528T HRP20210528T1 HR P20210528 T1 HRP20210528 T1 HR P20210528T1 HR P20210528T T HRP20210528T T HR P20210528TT HR P20210528 T HRP20210528 T HR P20210528T HR P20210528 T1 HRP20210528 T1 HR P20210528T1
Authority
HR
Croatia
Prior art keywords
peptide
cell
expression vector
cancer
nucleic acid
Prior art date
Application number
HRP20210528TT
Other languages
English (en)
Inventor
Andrea Mahr
Toni Weinschenk
Anita WIEBE
Jens Fritsche
Harpreet Singh
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507719.1A external-priority patent/GB201507719D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20210528T1 publication Critical patent/HRP20210528T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (16)

1. Peptid koji se sastoji od slijeda aminokiselina sukladno SEQ ID BR.: 22, ili njegova farmaceutski prihvatljiva sol, pri čemu navedeni peptid ima sposobnost vezanja na molekulu humanog kompleksa histokompatibilnosti (MHC) klase I, i pri čemu je spomenuti peptid, kada je vezan za MHC, sposoban biti prepoznat putem CD8 T-stanice.
2. Peptid prema zahtjevu 1, pri čemu navedeni peptid uključuje nepeptidne vezove, i/ili pri čemu je navedeni peptid dio fuzijskog proteina, koji sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
3. Antitijelo, topljivo ili na membranu vezano, koje posebno prepoznaje peptide prema zahtjevu 1 ili peptid prema zahtjevu 1 kada se veže za MHC-molekule.
4. T-stanični receptor (TCR), topljiv ili na membranu vezan, koji je reaktivan s HLA ligandom kada se veže za MHC molekulu, pri čemu se navedeni ligand sastoji od aminokiselinskog slijeda SEQ ID BR.: 22.
5. Nukleinska kiselina, koja kodira peptid u skladu s patentnim zahtjevom 1 ili 2, TCR prema zahtjevu 4 ili ekspresivni vektor koji eksprimira navedenu nukleinsku kiselinu.
6. Rekombinantna stanica domaćin koja sadrži peptid prema zahtjevu 1 ili 2, ili nukleinsku kiselinu ili ekspresijski vektor prema zahtjevu 5.
7. Rekombinantna stanica domaćin prema zahtjevu 6, pri čemu je navedena stanica domaćin stanica koja prezentira antigen za spomenutu nukleinsku kiselinu ili ekspresijski vektor koji kodira peptid, ili T-stanicu ili NK stanicu za spomenutu nukleinsku kiselinu ili ekspresijski vektor koji kodira TCR.
8. Metoda za proizvodnju peptida prema zahtjevu 1 ili 2 ili za proizvodnju T-staničnih receptora prema zahtjevu 4, metoda koja obuhvaća kultiviranje stanice domaćina prema zahtjevu 6 ili 7, koja predstavlja peptid prema zahtjevu 1 ili 2 ili ekspresivna nukleinska kiselina ili ekspresivni vektor prema zahtjevu 5 i izoliranje navedeni peptid ili navedeni TCR od stanice domaćina i/ili njezinog medija za kultiviranje.
9. In vitro metoda za proizvodnju aktiviranih T-limfocita, metoda je koja obuhvaća kontaktiranje in vitro T-stanica humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnom konstrukcijom koja oponaša stanicu koja predstavlja antigen u vremenskom razdoblju dovoljnom da se aktiviraju navedene T-stanice na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu sa zahtjevom 1.
10. Aktivirana T-stanica, proizvedena metodom u skladu s patentnim zahtjevom 9 koji selektivno prepoznaje stanicu koja predstavlja polipeptid koji sadrži sekvenciju aminokiseline sukladno zahtjevu 1.
11. Farmaceutski sastav koji uključuje najmanje jedan aktivni sastojak, koji je odabran iz grupe peptida prema zahtjevu 1 ili 2, antitijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinsku kiselinu ili ekspresivni vektor prema zahtjevu 5, rekombinantnu stanicu domaćina koja sadrži ekspresijski vektor prema zahtjevu 6 ili 7, aktiviranu T-stanicu prema zahtjevu 10 i farmaceutski prihvatljivog nositelja.
12. Peptid prema zahtjevu 1 ili 2, antitijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, rekombinantna stanica domaćin koja sadrži ekspresijski vektor prema zahtjevu 6 ili 7, aktivirana T-stanica prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 11 za uporabu u medicini.
13. Peptid prema zahtjevu 1 ili 2, antitijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, rekombinantna stanica domaćin koja sadrži ekspresijski vektor prema zahtjevu 6 ili 7, aktivirana T-stanica prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 11 za uporabu u liječenju karcinoma.
14. Peptid, antitijelo, TCR, nukleinska kiselina ili ekspresijski vektor, rekombinantna stanica domaćin, aktivirana T-stanica ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 13, naznačen time što je navedeni rak odabran iz skupine karcinoma pluća, rak mozga, rak jetre, rak bubrega, rak debelog crijeva, rak jetre, rak gušterače, rak prostate, leukemija, rak dojke, karcinom stanica Merkel, melanom, rak jajnika i rak jednjaka te drugi tumori koji pokazuju prekomjernu ekspresiju proteina iz kojeg je izveden peptid SEQ ID BR.: 22.
15. Komplet koji sadrži: Farmaceutski sastav koji uključuje najmanje jedan aktivni sastojak, koji je odabran iz grupe peptida prema zahtjevu 1 ili 2, antitijelo prema zahtjevu prema zahtjevu 3, nukleinsku kiselinu ili ekspresivni vektor prema zahtjevu 5, stanicu domaćina koja sadrži ekspresijski vektor prema zahtjevu 6 ili 7, ili aktiviranu T-stanicu prema zahtjevu 10 u otopini ili liofiliziranom obliku.
16. Komplet zahtjeva 15, koji sadrži drugu posudu koja sadrži diluens ili otopinu za rekonstituciju za liofiliziranu formulaciju.
HRP20210528TT 2015-05-06 2021-03-31 Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma HRP20210528T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562157684P 2015-05-06 2015-05-06
GBGB1507719.1A GB201507719D0 (en) 2015-05-06 2015-05-06 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
PCT/EP2016/060007 WO2016177784A1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
EP16723966.4A EP3291830B1 (en) 2015-05-06 2016-05-04 Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

Publications (1)

Publication Number Publication Date
HRP20210528T1 true HRP20210528T1 (hr) 2021-08-06

Family

ID=56026813

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210528TT HRP20210528T1 (hr) 2015-05-06 2021-03-31 Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma

Country Status (13)

Country Link
US (6) US20220356220A1 (hr)
JP (1) JP6985153B2 (hr)
CN (1) CN107810193B (hr)
CL (1) CL2017002766A1 (hr)
CO (1) CO2017010830A2 (hr)
CR (1) CR20230131A (hr)
CY (1) CY1124038T1 (hr)
HR (1) HRP20210528T1 (hr)
IL (2) IL308202A (hr)
MX (1) MX2022002263A (hr)
MY (1) MY185616A (hr)
PH (1) PH12017501994A1 (hr)
TW (2) TWI800770B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112816682B (zh) * 2021-01-28 2024-03-26 浙江省农业科学院 三螺旋dna分子开关探针及其在ota比色快速检测中的应用
JP2022186461A (ja) * 2021-06-04 2022-12-15 地方独立行政法人東京都健康長寿医療センター 前立腺がん治療用医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006166789A (ja) * 2004-12-15 2006-06-29 Hiroshima Univ 癌の新規診断方法
CN101168566A (zh) * 2006-10-26 2008-04-30 北京市肿瘤防治研究所 抗肿瘤特异性标志蛋白ts/medp的抗体制备及用途
EP2565204B1 (en) * 2007-07-27 2015-10-07 immatics biotechnologies GmbH Novel immunogenic epitopes for immunotherapy
US8492347B2 (en) * 2007-10-17 2013-07-23 The Regents Of The University Of California Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
SI2172211T1 (sl) * 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
US10137182B2 (en) * 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）

Also Published As

Publication number Publication date
CY1124038T1 (el) 2022-05-27
TWI800770B (zh) 2023-05-01
JP2018520644A (ja) 2018-08-02
US20230086855A1 (en) 2023-03-23
CR20230131A (es) 2023-06-23
CN107810193B (zh) 2022-03-22
IL308202A (en) 2024-01-01
JP6985153B2 (ja) 2021-12-22
US20220356220A1 (en) 2022-11-10
TW202124429A (zh) 2021-07-01
US20230203113A1 (en) 2023-06-29
CL2017002766A1 (es) 2018-03-23
US20230088845A1 (en) 2023-03-23
CO2017010830A2 (es) 2018-01-16
PH12017501994A1 (en) 2018-03-26
TW202330590A (zh) 2023-08-01
MX2022002263A (es) 2022-03-22
IL255126A0 (en) 2017-12-31
CN107810193A (zh) 2018-03-16
US20230203114A1 (en) 2023-06-29
MY185616A (en) 2021-05-25
US20230212244A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
HRP20191859T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2020198875A5 (hr)
JP2020182458A5 (hr)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
JP2020191862A5 (hr)
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
MY189042A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MX2018011223A (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer.
PH12018501933A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
JP2019515650A5 (hr)
HRP20230512T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
PH12018501892A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
EP3988563A3 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
HRP20200967T1 (hr) Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
HRP20211754T1 (hr) Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova